Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Antigen cross-presentation, wherein dendritic cells (DCs) present exogenous antigen on
major histocompatibility class I (MHC-I) molecules, is considered the primary mechanism by …

With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Simple Summary A new class of drugs, termed Immune Checkpoint Inhibitors, has
revolutionized cancer therapy during the last few years. Unfortunately, these drugs are only …

Antigen presentation machinery and professional antigen-presenting cells (APCs) are
fundamental for an efficacious immune response against cancers, especially in the context …

Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is gaining momentum and
demonstrating durable responses in patients with advanced melanoma. Although …

Incidence of early-onset colorectal cancer (EOCRC), defined by a diagnosed age under 50
years, is increasing, but its heterogeneous etiologies that differ from general CRC remain …

The introduction of immune checkpoint inhibitors has changed the therapeutic possibilities
for various cancer types. However, despite the success in some entities, a significant fraction …